shares angloswedish closed 8 uk trade failure iressa major clinical trial
lung cancer significantly prolong survival patients disease
setback group follows rejection us october anticoagulant pill exanta
meanwhile another major money spinners cholesterol crestor facing mounting safety concerns
would two three blockbuster drugs meant power company forward failing
weve got risks crestor said nick turner analyst brokers jefferies
astrazeneca hoped pitch iressa rival medicine tarceva
iressa proved better placebo extending lives trial involving 1692 patients
tarceva made osi pharmaceuticals genentech roche already proved successful helping prolong life lung cancer patients
aztrazeneca appointed new executive director board
john patterson charge development
company said mr patterson would make substantial changes clinical organisation processes
determined improve development regulatory performance restore confidence company value shareholders said chief executive tom mckillop

